Get started
Author

Hao Zeng

The tumor‐repressing effect of CYP27A1 on renal cell carcinoma by 27‐HC arising from cholesterol metabolism
2022 · Xingming Zhang, Xiaoxue Yin, et al. · The FASEB Journal · 9
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
2023 · Ming-Hao Wang, Jin-Dong Dai, et al. · Asian Journal of Andrology · 4
Targeting YAP1-CD70 axis potentiates the efficacy of anti-PD-1 therapy in prostate cancer
2026 · Tongyu Tong, Yupeng Guan, et al. · Biomarker Research · 3
PDF
The JAK/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications
2026 · Yixing Liao, Qi Wei, et al. · MedComm – Oncology · 1
A boost or a redundancy? on the value of combination of androgen receptor signal inhibitor and PARP inhibitor for advanced prostate cancer
2024 · Qihao Wang, Jianjun Ye, et al. · Holistic Integrative Oncology · 1
PDF
TLR7 Agonist Nanomedicine Suppresses Lung Metastasis of Osteosarcoma by Remodeling the Immune Microenvironment
2026 · Xinyue Zhang, Hao Zeng, et al. · MedComm – Oncology
HIRA loss is frequent but not universal in human fumarate hydratase-deficient renal cell carcinoma and defines divergent oncogenic programs
2026 · Xu Shi, Zehua Tan, et al. · Biomarker Research
PDF
Association of the triglyceride-glucose index with prostate cancer risk and prognosis: a systematic review and meta-analysis
2026 · Haobo Cao, Sike He, et al. · World Journal of Surgical Oncology
Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance
2026 · Ling Wang, Yanfeng Tang, et al. · Expert Opinion on Investigational Drugs
Safety, Feasibility and Prognostic Analysis of Surgical Treatment for High‐Complexity Renal Tumours (RENAL Score ≥ 10): A Summary of Experience With Robotic Technology Applications
2026 · Lijing Xu, Jialin Wang, et al. · International Journal of Medical Robotics and Computer Assisted Surgery
Clinical implications of prostate specific antigen (PSA) flare and response dynamics in TALAPRO-2: A post-hoc analysis.
2026 · Steven Yip, Hao Zeng, et al. · Journal of Clinical Oncology
PDF
Aggressive-variant prostate cancer features and therapeutic outcomes in patients with de-novo metastatic hormone-sensitive prostate cancer.
2026 · Qiyu Zhu, Zeqi Wang, et al. · Journal of Clinical Oncology
PDF
Intratumoral mature TLSs to predict response to ICI rechallenge in non–clear cell renal cell carcinoma.
2026 · Yanfeng Tang, Junru Chen, et al. · Journal of Clinical Oncology
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with histologic variants of prostate cancer.
2026 · Zehua Tan, Yifu Shi, et al. · Journal of Clinical Oncology
PDF
Real-world evaluation of olaparib combined with novel hormone therapy in metastatic castration-resistant prostate cancer with intraductal adenocarcinoma.
2026 · Qiyu Zhu, Ling Wang, et al. · Journal of Clinical Oncology
PDF
A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non-clear cell renal cell carcinoma.
2026 · Xu Hu, Xu Shi, et al. · Journal of Clinical Oncology
487O Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): Phase III CAPItello-281 Chinese subgroup analysis
2025 · W. Chen, D. Ye, et al. · Annals of Oncology
Drug treatment options of high-risk biochemically recurrent prostate cancer based on efficacy and safety: a systematic review and Bayesian network analysis
2025 · Qian Wang, Qiyu Zhu, et al. · European journal of medical research
PDF
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.
2025 · Xiaojie Bian, Hao Zeng, et al. · Journal of Clinical Oncology
PDF
Liquid-based kidney injury molecule-1 (KIM-1) as a diagnostic and prognostic indicator in renal cell carcinoma: A systematic review and meta-analysis.
2025 · Sike He, Junru Chen, et al. · Journal of Clinical Oncology
PDF
Interpretable machine learning for prostate biopsy: Cohort study.
2025 · Jindong Dai, Jinge Zhao, et al. · Journal of Clinical Oncology
PDF
Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.
2025 · Yanfeng Tang, Minghao Wang, et al. · Journal of Clinical Oncology
PDF
Use of integrated multi-omics analysis to analyze prognostic molecular subtype in collecting duct carcinoma.
2025 · Xiaowen Wu, Yiqiang Liu, et al. · Journal of Clinical Oncology
PDF
[Succinate Dehydrogenase-Deficient Renal Cell Carcinoma: Clinicopathological Analysis of 11 Cases].
2024 · Xiuyi Pan, Yuyan Wei, et al. · PubMed
PDF
Multi-omics analyses and molecular subtypes to provide potential therapeutic implications in fumarate hydratase-deficient renal cell carcinoma.
2024 · Xingming Zhang, Junjie Zhao, et al. · Journal of Clinical Oncology
Works count: 28
Citation count: 18
H-index: 3
I10-index:
Year
Topic
Type